Clinuvel, FDA To Discuss NDA For Phototoxicity Drug Scenesse
This article was originally published in The Pink Sheet Daily
Executive Summary
The Australian firm will discuss the possibility of an accelerated assessment for Scenesse to treat light intolerance and whether the risk-management program it agreed with the European Medicines Agency after EU approval last year will satisfy the FDA's demands as well.